Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma
- Author
- HANSEN, Steen Werner1
[1] National Board of Health, Copenhagen, Denmark - Issue title
- Gemcitabine: defining the future of ovarian cancer therapy
- Author (monograph)
- OZOLS, Robert F (Editor)1
[1] Fox Chase Cancer Center, Philadelphia, PA 19111, United States - Source
Seminars in oncology. 2002, Vol 29, Num 1, pp 17-19 ; SUP1 ; ref : 17 ref
- CODEN
- SOLGAV
- ISSN
- 0093-7754
- Scientific domain
- Medical oncology
- Publisher
- Elsevier, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Agent alkylant Anticancéreux Antimitotique Antimétabolite Association médicamenteuse Carboplatine Carcinome Chimiothérapie Cisplatine Fluor Composé organique Gemcitabine Homme Ovaire Paclitaxel Platine II Complexe Pyrimidine nucléoside Stade avancé Taxane dérivé Traitement Appareil génital femelle pathologie Ovaire pathologie Tumeur maligne
- Keyword (en)
- Alkylating agent Antineoplastic agent Antimitotic Antimetabolic Drug combination Carboplatin Carcinoma Chemotherapy Cisplatin Fluorine Organic compounds Gemcitabine Human Ovary Paclitaxel Platinum II Complexes Pyrimidine nucleoside Advanced stage Taxane derivatives Treatment Female genital diseases Ovarian diseases Malignant tumor
- Keyword (es)
- Agente alquilante Anticanceroso Antimitótico Antimetabólito Asociación medicamentosa Carboplatino Carcinoma Quimioterapia Cisplatino Fluor Compuesto orgánico Gemcitabina Hombre Ovario Paclitaxel Platino II Complejo Pirimidina nucleósido Estadio avanzado Taxane derivado Tratamiento Aparato genital hembra patología Ovario patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 13512091
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1053/sonc.2002.31593 
https://dx.doi.org/10.1053/sonc.2002.31593
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1053\/sonc.2002.31593\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Seminars in oncology\";s:9:\"\u0000*\u0000stitle\";s:12:\"Semin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"17\";s:8:\"\u0000*\u0000epage\";s:2:\"19\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0093-7754\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HANSEN\";s:10:\"\u0000*\u0000aufirst\";s:12:\"Steen Werner\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SOLGAV\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUP1\";s:9:\"\u0000*\u0000btitle\";s:58:\"Gemcitabine: defining the future of ovarian cancer therapy\";s:8:\"\u0000*\u0000title\";s:90:\"Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1053\/sonc.2002.31593\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Seminars in oncology\";s:9:\"\u0000*\u0000stitle\";s:12:\"Semin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"17\";s:8:\"\u0000*\u0000epage\";s:2:\"19\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0093-7754\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HANSEN\";s:10:\"\u0000*\u0000aufirst\";s:12:\"Steen Werner\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SOLGAV\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUP1\";s:9:\"\u0000*\u0000btitle\";s:58:\"Gemcitabine: defining the future of ovarian cancer therapy\";s:8:\"\u0000*\u0000title\";s:90:\"Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:23:\"10.1053\/sonc.2002.31593\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1053\/sonc.2002.31593\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Seminars in oncology\";s:9:\"\u0000*\u0000stitle\";s:12:\"Semin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"17\";s:8:\"\u0000*\u0000epage\";s:2:\"19\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0093-7754\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HANSEN\";s:10:\"\u0000*\u0000aufirst\";s:12:\"Steen Werner\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SOLGAV\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUP1\";s:9:\"\u0000*\u0000btitle\";s:58:\"Gemcitabine: defining the future of ovarian cancer therapy\";s:8:\"\u0000*\u0000title\";s:90:\"Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1053\/sonc.2002.31593\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Seminars in oncology\";s:9:\"\u0000*\u0000stitle\";s:12:\"Semin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"17\";s:8:\"\u0000*\u0000epage\";s:2:\"19\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0093-7754\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HANSEN\";s:10:\"\u0000*\u0000aufirst\";s:12:\"Steen Werner\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SOLGAV\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUP1\";s:9:\"\u0000*\u0000btitle\";s:58:\"Gemcitabine: defining the future of ovarian cancer therapy\";s:8:\"\u0000*\u0000title\";s:90:\"Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1053\/sonc.2002.31593\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Seminars in oncology\";s:9:\"\u0000*\u0000stitle\";s:12:\"Semin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"17\";s:8:\"\u0000*\u0000epage\";s:2:\"19\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0093-7754\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HANSEN\";s:10:\"\u0000*\u0000aufirst\";s:12:\"Steen Werner\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SOLGAV\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUP1\";s:9:\"\u0000*\u0000btitle\";s:58:\"Gemcitabine: defining the future of ovarian cancer therapy\";s:8:\"\u0000*\u0000title\";s:90:\"Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
